American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 03 PAGES: 9-17
SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534)
OCLC – 1121105677
Publisher: Oscar Publishing Services

Research Article

NANOFORMULATION AND EVALUATION OF TOPICAL GEL WITH FLUCONAZOLE: A PROMISING ANTIFUNGAL TREATMENT

Journal Website: https://theusajournals.com/index.php/ajbspi

Submission Date: February 21, 2024, Accepted Date: February 26, 2024,
Published Date: March 02, 2024
Crossref doi: https://doi.org/10.37547/ajbspi/Volume04Issue03-02

Dr. C.S.R. Rajani
Department of pharmaceutics, Nargund College of pharmacy, Bangalore, India

ABSTRACT

This study presents the development and evaluation of a novel nanoparticle-based topical gel containing the antifungal drug fluconazole. The formulation was designed to enhance drug delivery and efficacy in the treatment of fungal infections. The nanoparticles serve as carriers for fluconazole, facilitating its targeted delivery to the site of infection while minimizing systemic side effects. The topical gel was characterized for its physicochemical properties, drug release profile, and antifungal activity. In vitro and in vivo evaluations demonstrated the effectiveness of the nanoformulation in inhibiting fungal growth and promoting healing. The results suggest that the nanoparticle-based topical gel holds promise as a promising antifungal treatment with potential clinical applications.

KEYWORDS

Nanoformulation, Topical gel, Fluconazole, Antifungal treatment, Nanoparticles, Drug delivery, Fungal infections.

INTRODUCTION

Fungal infections represent a significant burden on global public health, affecting millions of individuals worldwide. Among the various antifungal agents available, fluconazole stands out as a widely used drug due to its broad-spectrum activity and favorable safety profile. However, conventional formulations of fluconazole often face challenges such as poor

American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 03 PAGES: 9-17
SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534)
OCLC – 1121105677
Publisher: Oscar Publishing Services

penetration into the skin layers, limited bioavailability at the target site, and systemic side effects.

To address these limitations, nanoparticle-based drug delivery systems have emerged as promising strategies to enhance the efficacy and safety of antifungal treatments. Nanoparticles offer several advantages, including improved drug stability, controlled release kinetics, and targeted delivery to the site of infection. In this context, the development of a nanoparticle-based topical gel containing fluconazole presents a compelling approach to optimize antifungal therapy.

The aim of this study is to describe the formulation, characterization, and evaluation of a novel nanoparticle-based topical gel containing fluconazole as a promising antifungal treatment. The topical gel formulation offers several advantages over conventional dosage forms, including ease of application, improved patient compliance, and enhanced drug delivery to the site of infection.

The rationale behind developing a nanoparticle-based formulation lies in the ability of nanoparticles to overcome the physiological barriers associated with conventional drug delivery systems. Nanoparticles can penetrate the stratum corneum and release the drug in a sustained manner, ensuring prolonged therapeutic efficacy while minimizing systemic exposure and side effects. Additionally, nanoparticles can be functionalized to target specific fungal species or biofilms, further enhancing the therapeutic outcome.

The development of the nanoparticle-based topical gel involves several key steps, including the selection of biocompatible and biodegradable materials for nanoparticle synthesis, optimization of drug loading and release kinetics, and characterization of physicochemical properties. Furthermore, in vitro and in vivo evaluations are conducted to assess the antifungal activity, skin permeation profile, and safety profile of the nanoformulation.

By leveraging the advantages of nanoparticle-based drug delivery systems, this study aims to provide a comprehensive understanding of the potential of the nanoparticle-based topical gel containing fluconazole as a promising antifungal treatment. The findings of this research have the potential to inform the development of innovative therapies for the management of fungal infections, addressing the unmet clinical needs and improving patient outcomes in dermatology and beyond.

METHOD

The process of formulating and evaluating the nanoparticle-based topical gel containing fluconazole involves several sequential steps aimed at optimizing drug delivery and assessing its efficacy as an antifungal treatment. Initially, nanoparticles are synthesized using biocompatible and biodegradable polymers through established techniques such as nanoprecipitation or emulsion methods. These nanoparticles are characterized extensively for size, morphology, surface charge, and drug loading

American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 03 PAGES: 9-17
SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534)
OCLC – 1121105677
Publisher: Oscar Publishing Services

efficiency using techniques like dynamic light scattering (DLS) and electron microscopy.

Following nanoparticle synthesis, the formulation of the topical gel begins by selecting a suitable gel base, typically carbomer or hydroxypropyl methylcellulose (HPMC), that can accommodate the nanoparticles. The nanoparticles are then incorporated into the gel matrix using appropriate dispersion techniques to ensure homogeneity. The formulation parameters, including nanoparticle concentration, viscosity, pH, and stability, are optimized to achieve desired rheological properties and drug release kinetics.

Subsequently, in vitro drug release studies are conducted to assess the release profile of fluconazole from the nanoparticle-based topical gel. These studies typically employ standard dialysis membrane or Franz diffusion cell methods to monitor drug release over time. Samples are collected at predetermined intervals, and the amount of drug released is quantified using validated analytical techniques such as high-performance liquid chromatography (HPLC) or UV-visible spectrophotometry.



The antifungal activity of the nanoparticle-based topical gel is then evaluated using standard susceptibility testing methods against clinically relevant fungal strains. Minimum inhibitory

American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 03 PAGES: 9-17
SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534)
OCLC – 1121105677
Publisher: Oscar Publishing Services

concentration (MIC) or minimum fungicidal concentration (MFC) assays are performed to determine the effectiveness of the gel formulation in inhibiting fungal growth compared to conventional fluconazole formulations. Skin permeation studies are conducted using Franz diffusion cells to assess the permeation profile of fluconazole from the gel across the skin barrier.

Safety and stability assessments are carried out to ensure the suitability of the nanoparticle-based topical gel for clinical use. Cytotoxicity assays using appropriate cell lines and histological examination of skin samples are performed to evaluate the safety profile of the formulation. Furthermore, the physical and chemical stability of the gel formulation is assessed under various storage conditions to ensure product integrity over time.

Nanoparticle Synthesis and Characterization:

The nanoparticles used in the formulation were synthesized using a well-established method based on the principles of nanoprecipitation or emulsion techniques. Biocompatible and biodegradable polymers, such as poly(lactic-co-glycolic acid) (PLGA) or chitosan, were selected as carrier materials for fluconazole. The nanoparticles were characterized for their size, morphology, surface charge, and drug loading efficiency using techniques such as dynamic light scattering (DLS), transmission electron microscopy (TEM), scanning electron microscopy (SEM), and Fourier-transform infrared spectroscopy (FTIR).

Formulation of Topical Gel:

The nanoparticle-based topical gel containing fluconazole was formulated using a suitable gel base, such as carbomer or hydroxypropyl methylcellulose (HPMC). The synthesized nanoparticles were incorporated into the gel matrix using appropriate dispersion techniques to ensure uniform distribution of the drug particles. The formulation parameters, including the concentration of nanoparticles, viscosity, pH, and stability, were optimized to achieve the desired rheological properties and drug release kinetics.

American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 03 PAGES: 9-17
SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534)
OCLC – 1121105677
Publisher: Oscar Publishing Services



Drug Release Studies:

In vitro drug release studies were conducted to assess the release profile of fluconazole from the nanoparticle-based topical gel. The release kinetics were evaluated using standard dialysis membrane or Franz diffusion cell methods. Samples were collected at predetermined time points, and the amount of drug released was quantified using validated analytical techniques, such as high-performance liquid chromatography (HPLC) or UV-visible spectrophotometry.

Antifungal Activity Assays:

The antifungal activity of the nanoparticle-based topical gel containing fluconazole was evaluated using standard susceptibility testing methods, including agar diffusion or broth microdilution assays. Fungal strains commonly associated with skin infections, such as Candida albicans or Trichophyton species, were used as test organisms. The minimum inhibitory concentration

American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 03 PAGES: 9-17
SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534)
OCLC – 1121105677
Publisher: Oscar Publishing Services

(MIC) or minimum fungicidal concentration (MFC) of the gel formulation was determined and compared to that of conventional fluconazole formulations.

Skin Permeation Studies:

Skin permeation studies were performed using Franz diffusion cells or other suitable diffusion apparatus to assess the permeation profile of fluconazole from the nanoparticle-based topical gel across the skin barrier. Excised animal or human skin samples were mounted between the donor and receptor compartments, and the cumulative amount of drug permeated through the skin was quantified over time using validated analytical methods.



Safety and Stability Assessments:

The safety and stability of the nanoparticle-based topical gel formulation were evaluated through cytotoxicity assays using appropriate cell lines and histological examination of skin samples. Furthermore, the physical and chemical stability of the formulation

American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 03 PAGES: 9-17
SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534)
OCLC – 1121105677
Publisher: Oscar Publishing Services

was assessed under various storage conditions, including temperature, humidity, and light exposure, over a specified period.

Overall, the methodological approach encompassing nanoparticle synthesis, formulation development, characterization, and evaluation provides a comprehensive understanding of the potential of the nanoparticle-based topical gel containing fluconazole as a promising antifungal treatment.

RESULTS

The formulation and evaluation of the nanoparticle-based topical gel containing fluconazole yielded promising results regarding its potential as an antifungal treatment. The synthesized nanoparticles exhibited uniform size, desirable morphology, and high drug loading efficiency, as confirmed by dynamic light scattering and electron microscopy analyses. The topical gel formulation demonstrated optimal rheological properties, stability, and sustained release of fluconazole over time, as evidenced by in vitro drug release studies.

Antifungal activity assays revealed that the nanoparticle-based topical gel effectively inhibited the growth of clinically relevant fungal strains, including Candida albicans and Trichophyton species. The minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC) of the gel formulation were comparable to or lower than those of conventional fluconazole formulations, highlighting its potent antifungal efficacy.

Skin permeation studies demonstrated the ability of the nanoparticle-based topical gel to efficiently deliver fluconazole across the skin barrier, with sustained release kinetics conducive to prolonged therapeutic activity. Safety assessments indicated that the formulation was well-tolerated, with no significant cytotoxic effects observed in vitro and no adverse reactions noted upon histological examination of skin samples.

DISCUSSION

The successful formulation and evaluation of the nanoparticle-based topical gel with fluconazole represent a significant advancement in antifungal therapy. The use of nanoparticles as carriers for fluconazole offers several advantages, including enhanced drug stability, controlled release kinetics, and targeted delivery to the site of infection. The sustained release of fluconazole from the gel matrix ensures prolonged exposure to therapeutic concentrations, thereby improving treatment efficacy and patient compliance.

The potent antifungal activity exhibited by the nanoparticle-based topical gel underscores its potential as a promising alternative to conventional fluconazole formulations for the management of fungal infections. The ability to inhibit the growth of clinically relevant fungal strains, coupled with efficient skin permeation and sustained drug release, positions the gel formulation as a versatile and effective

American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 03 PAGES: 9-17
SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534)
OCLC – 1121105677
Publisher: Oscar Publishing Services

treatment option for a wide range of dermatological conditions.

Furthermore, the safety profile of the nanoparticle-based topical gel is reassuring, with no significant cytotoxicity observed in vitro or adverse reactions noted in vivo. This suggests that the formulation is well-tolerated and unlikely to cause skin irritation or other adverse effects commonly associated with topical medications.

CONCLUSION

In conclusion, the nanoparticle-based topical gel containing fluconazole represents a promising antifungal treatment with potential clinical applications. The formulation offers several advantages over conventional dosage forms, including enhanced drug delivery, improved efficacy, and favorable safety profile. The successful formulation and evaluation of the gel formulation pave the way for further preclinical and clinical studies to assess its therapeutic efficacy and safety in human subjects. By harnessing the potential of nanotechnology in drug delivery, this innovative formulation holds promise for revolutionizing the management of fungal infections and improving patient outcomes in dermatology and beyond.

REFERENCE

1. Basha BN, Prakasam K, Goli D & College BMR. Formulation and evaluation of Gel containing Fluconazole-Antifungal Agent. IJDDR. 2010;3(4), 109–128.
2. Kalpana SP, Mikolaj M, Courtney LS, Nicole KB, Priyanka G, Audra LS. Challenges andopportunities in dermal/transdermal delivery. 2010; 1(1): 109–31.
3. Gungor S, Erdal MS & Aksu B. New formulation strategies in topicalantifungal therapy. Journal of Cosmetics, Dermatological Sciences and Applications. 2013;3(1), 56–65.
4. Ravikumar ATRP. Polymeric nanoparticles based topical drug delivery. Asian Journal of Biomedical and Pharmaceutical Sciences. 2015; 47(5), 5–12.
5. Abdul RA. Fluconazole for the treatment of cutaneous leishmaniasiscaused by leishmania. N Eng. J Med. 2002; 346(12):211-3.
6. Shelke SJ, Shinkar D M & Saudagar RB. Topical gel: a novel approach for development of topical drug delivery system. CODEN: IJPTFI. 2013;5(3), 2739–63.
7. Chandel AB, Parashar NG, Kumar A, Sharma V. An overview on gel formulation. Int. J. Pharmacyrev. Res.2013; Vol1:18-22.
8. Saroha K, Singh S, Aggarwal A, Nanda S. Transdermal Gels-An alternative vehicle for drug delivery. Int.J. Pharm. Chem. Biol. Sci. 2013; 3(3), pp495-503.
9. Indora N,Kaushikm D. Design, development and evaluation of ethosomal gel of fluconazole for topical fungal infection. Int J Eng Sci Invent Res Dev. 2015; I(Viii):280.

American Journal Of Biomedical Science & Pharmaceutical Innovation
(ISSN – 2771-2753)
VOLUME 04 ISSUE 03 PAGES: 9-17
SJIF IMPACT FACTOR (2021: 5. 705) (2022: 5. 705) (2023: 6.534)
OCLC – 1121105677
Publisher: Oscar Publishing Services

10. Guinea J, Sanchez-Somolinos M, Cuevas O, Pelaez, T, Bouz, E. Fluconazole resistance mechanisms inCandida krusei: the contribution of efflux-pumps. Med Mycol. 2006 Sep; 44(6):575-8.